Current concepts in the evaluation and treatment of neurofibromatosis type II

Otolaryngologic Clinics of North America

Volumn 38, Issue 4, 2005, Pages 671-684

  Neff, Brian A ^a   Welling, D Bradley ^b  

^a MAYO CLINIC   (United States)

^b THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER RADIOTHERAPY; CANCER SURGERY; CLINICAL FEATURE; CLINICAL TRIAL; DIAGNOSTIC PROCEDURE; FUNCTIONAL ASSESSMENT; GENETIC SCREENING; HEARING; HEARING LOSS; HUMAN; MUTATION; NEUROFIBROMATOSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; REVIEW; SURGICAL TECHNIQUE; TUMOR GROWTH; TUMOR LOCALIZATION; TUMOR VOLUME; VASCULARIZATION;

DECOMPRESSION, SURGICAL; GENETIC SCREENING; HEARING LOSS; HUMANS; MAGNETIC RESONANCE IMAGING; NEUROFIBROMATOSIS 2;

EID: 22244481829     PISSN: 00306665     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.otc.2005.01.002     Document Type: Review

References (61)

1. Prevention and control of neurofibromatosis: memorandum from a joint WHO/NNFF meeting Bull World Health Organ 70 1992 173 182
2. D.G. Evans, S.M. Huson, and D. Donnai A genetic study of type 2 neurofibromatosis in the United Kingdom: I. Prevalence, mutation rate, fitness, and confirmation of maternal transmission effect on severity J Med Genet 29 1992 841 846
3. B. Fontaine, G.A. Rouleau, and B.R. Seizinger Molecular genetics of neurofibromatosis 2 and related tumors (acoustic neuroma and meningioma) Ann N Y Acad Sci 615 1991 338 343
4. M. Kaiser-Kupfer, V. Freidlin, and M.B. Datiles The association of posterior capsular lens opacities with bilateral acoustic neuromas in patients with neurofibromatosis type 2 Arch Ophthalmol 107 4 1989 541 544
5. W.R. Kanter, R. Eldridge, and R. Fabricant Central neurofibromatosis with bilateral acoustic neuroma: genetic, clinical and biochemical distinctions from peripheral neurofibromatosis Neurology 30 1980 851 859
6. R.L. Martuza, and R. Eldridge Neurofibromatosis 2 (bilateral acoustic neurofibromatosis) N Engl J Med 318 1988 684 688
7. M.E. Glasscock III, C.I. Woods, and C.G. Jackson Management of bilateral acoustic tumors Laryngoscope 99 1989 475 484
8. V.F. Mautner, M. Lindenau, and M.E. Baser Skin abnormalities in neurofibromatosis 2 Arch Dermatol 133 1997 1539 1543
9. D.G.R. Evans, M. Sainio, and M.E. Baser Neurofibromatosis type 2 J Med Genet 37 2000 897 904
10. M.E. Baser, J.M. Friedman, and A.J. Wallace Evaluation of clinical diagnostic criteria for neurofibromatosis 2 Neurology 59 11 2002 1759 1765
11. D.A. Marchuk, A.M. Saulino, and R. Tavakkol cDNA cloning of the type 1 neurofibromatosis gene: complete sequence of the NF1 gene product Genomics 11 4 1991 931 940
12. J.A. Trofatter, M.M. MacCollin, and J.L. Rutter A novel Moesin-, Exrin-, Radixin-like gene is a candidate for the neurofibromatosis 2 tumor-suppressor Cell 72 1993 791 800
13. D.G.R. Evans, S.M. Huson, and D. Donnai A clinical study of type 2 neurofibromatosis Q J Med 84 1992 603 618
14. J.H. Wishart Case of tumors in the skull, dura mater, and brain Edinburgh Med Surg J 18 1822 393 397
15. W.J. Gardner, and C.H. Frazier Bilateral acoustic neurofibromatosis: a clinical study and field survey of a family of five generations with bilateral deafness in thirty-eight members Arch Neurol Psychiatry 23 1930 266 302
16. M. Ruggieri, and S.M. Huson The clinical and diagnostic implications of mosaicism in neurofibromatosis Neurology 56 11 2001 1433 1443
17. L. Kluwe, V. Mautner, and B. Heinrich Molecular study of frequency of mosaicism in neurofibromatosis 2 patients with bilateral vestibular schwannomas J Med Genet 40 2 2003 109 114
18. A. Moyhuddin, M.G. Baser, and C. Watson Somatic mosaicism in neurofibromatosis 2: prevalence and risk of disease transmission to offspring J Med Genet 40 6 2003 459 463
19. D.G.R. Evans, J.M. Birch, and R. Ramsden Pediatric presentation of type 2 neurofibromatosis Arch Dis Child 81 1999 496 499
20. V.F. Mautner, M. Lindenau, and M.E. Baser Spinal tumors in patients with neurofibromatosis type 2: MR imaging study of frequency, multiplicity, and variety AJR Am J Roentgenol 165 1995 951 955
21. D.A. Moffat, N. Quaranta, and D.M. Baguley Management strategies in neurofibromatosis type 2 Eur Arch Otorhinolaryngol 260 2003 12 18
22. V.F. Mautner, M. Lindenau, and M.E. Baser The neuroimaging and clinical spectrum of neurofibromatosis 2 Neurosurgery 38 1996 880 885
23. D.B. Welling, M.E. Glasscock III, and C.I. Woods Acoustic neuroma: a cost-effective approach Otolaryngol Head Neck Surg 103 3 1990 364 370
24. I.A. Zealley, R.C. Cooper, and K.M. Clifford MRI screening for acoustic neuroma: a comparison of fast spin echo and contrast enhanced imaging in 1233 patients Br J Radiol 73 867 2000 242 247
25. D.B. Welling, M. Guida, and F. Goll Mutational spectrums in the neurofibromatosis type 2 gene in sporadic and familial schwannomas Hum Genet 98 1996 189 193
26. P. Merel, H.X. Khe, and M. Sanson Screening for germ-line mutations in the NF2 gene Genes Chromosomes Cancer 12 1995 117 127
27. M. MacCollin, V. Ramesh, and L.B. Jacoby Mutational analysis of patients with neurofibromatosis 2 Am J Hum Genet 55 1994 314 320
28. J. Zucman-Rossi, P. Legoix, and H. Der Sarkissian NF2 gene in neurofibromatosis type 2 patients Hum Mol Genet 7 1999 2095 2101
29. D.B. Welling Clinical manifestations of mutations in the neurofibromatosis type 2 gene in vestibular schwannomas (acoustic neuromas) Laryngoscope 108 1998 178 189
30. Welling DB, Neff BA, Wiet M, et al. Cochlear implantation in the profoundly deafened NF2 patient. Presented at the VIII International Cochlear Implant Conference, Indianapolis, IN, May 10-13, 2004.
31. R.A. Hoffman, D. Kohan, and N.L. Cohen Cochlear implants in the management of bilateral acoustic neuromas Am J Otol 13 6 1992 525 528
32. R.H. Temple, P.R. Axon, and R.T. Ramsden Auditory rehabilitation in neurofibromatosis type 2: a case for cochlear implantation J Laryngol Otol 113 2 1999 161 163
33. G.F. Hulka, E.J. Bernard, and H.C. Pillsbury Cochlear implantation in a patient after removal of an acoustic neuroma. The implications of magnetic resonance imaging with gadolinium on patient management Arch Otolaryngol Head Neck Surg 121 4 1995 465 468
34. S.R. Otto, D.E. Brackmann, and W.E. Hitselberger Multichannel auditory brainstem implants: update on performance in 61 patients J Neurosurg 96 6 2002 1063 1071
35. B. Nevison, R. Laszig, and W.P. Sollmann Results from a European clinical investigation of the nucleus multichannel auditory brainstem implant Ear Hear 23 3 2002 170 183
36. K. Ebinger, S. Otto, and J. Arcaroli Multichannel auditory brainstem implant: US clinical trial results J Laryngol Otol Suppl 27 2000 50 53
37. Shannon RV, Otto S, Brackmann DE, et al. Psychophysical and speech results from the first patients with the penetrating auditory brainstem implant (PABI). Presented at the VIII International Cochlear Implant Conference, Indianapolis, IN, May 10-13, 2004.
38. D.E. Brackmann, J.N. Fayad, and W.H. Slattery Early proactive management of vestibular schwannomas in neurofibromatosis type 2 Neurosurgery 49 2 2001 274 283
39. M. Samii, C. Matthies, and M. Tatagiba Management of vestibular schwannomas (acoustic neuromas): auditory and facial nerve function after resection of 120 vestibular schwannomas in patients with neurofibromatosis 2 Neurosurgery 40 4 1997 696 706
40. G.B. Hughes, A. Sismanis, and M.E. Glasscock III Management of bilateral acoustic neuromas Laryngoscope 92 1982 1351 1359
41. F.H. Linthicum Unusual audiometric and histologic findings in bilateral acoustic neurinomas Ann Otol 81 1972 433 437
42. J. Jääskeläinen, A. Paetau, and I. Pyykkö Interface between the facial nerve and large acoustic neurinomas. Immunohistochemical study of the cleavage plane in NF2 and non-NF2 cases J Neurosurg 80 1994 541 547
43. R.J.S. Briggs, D.E. Brackmann, and M.E. Baser Comprehensive management of bilateral acoustic neuromas Arch Otolaryngol Head Neck Surg 120 1994 1307 1314
44. A.K. Gadre, J.A. Kwartler, and D.E. Brackmann Middle fossa decompression of the internal auditory canal in acoustic neuroma surgery: a therapeutic alternative Laryngoscope 100 1990 948 952
45. W.H. Slattery, D.E. Brackmann, and W. Hitselberger Hearing preservation in neurofibromatosis type 2 Am J Otol 19 5 1998 638 643
46. M.E. Glasscock III, M.J. Hart, and J.T. Vrabec Management of bilateral acoustic neuromas Otolaryngol Clin North Am 25 1992 449 469
47. J.G. Rowe, M.W.R. Radatz, and L. Walton Clinical experience with gamma knife stereotactic radiosurgery in the management of vestibular schwannomas secondary to type 2 neurofibromatosis J Neurol Neurosurg Psychiatry 74 2003 1288 1293
48. B.E. Pollack, L.D. Lunsford, and D. Kondziolka Vestibular schwannoma management: II. Failed radiosurgery and the role of delayed microsurgery J Neurosurg 89 1998 949 955
49. R.A. Battista, and R.J. Wiet Stereotactic radiosurgery for acoustic neuromas: a survey of the American neurotology society Am J Otol 21 2000 371 381
50. M. Schulder, S.S. Gangadhar, and J.A. Kwartler Microsurgical removal of a vestibular schwannoma after stereotactic radiosurgery: surgical and pathological findings Am J Otol 20 1999 364 368
51. W.H. Slattery, and D.E. Brackmann Results of surgery following stereotactic irradiation for acoustic neuromas Am J Otol 16 3 1995 315 321
52. D.J. Lee, W.H. Westra, and H. Staecker Clinical and histopathologic features of recurrent vestibular schwannoma (acoustic neuroma) after stereotactic radiosurgery Otol Neurotol 24 4 2003 650 660
53. B.R. Subach, D. Kondziolka, and L.D. Lunsford Stereotactic radiosurgery in the management of acoustic neuromas associated with neurofibromatosis type 2 J Neurosurg 90 1999 815 822
54. R.J. Shaw, J.G. Paez, and M. Curto The Nf2 tumor suppressor, merlin, functions in Rac-dependent signaling Dev Cell 1 2001 63 72
55. J.L. Kissil, K.C. Johnson, and M.S. Eckman Merlin phosphorylation by p21-activated kinase 2 and effects of phosphorylation on merlin localization J Biol Chem 277 2002 10394 10399
56. G.H. Xiao, A. Beeser, and J. Chernoff p21-activated kinase links Rac/Cdc42 signaling in merlin J Biol Chem 277 2002 883 886
57. C. Allal, A. Pradines, and A.D. Hamilton Farnestylated RhoB prevents cell cycle arrest and actin cytoskeleton disruption caused by the geranylgeranyltransferase I inhibitor GGTI-298 Cell Cycle 1 6 2002 430 437
58. Y. Takamiya, R.M. Friedlander, and H. Brem Inhibition of angiogenesis and growth of human nerve-sheath tumors by AGM-1470 J Neurosurg 78 1993 470 476
59. D.B. Welling, J.M. Lasak, and E.M. Akhmametyeva cDNA microarray analysis of vestibular schwannomas Otol Neurotol 23 5 2002 736 748
60. P. Vajkoczy, M.D. Menger, and B. Vollmar Inhibition of tumor growth, angiogenesis, and microcirculation by the novel Flk-1 inhibitor SU-5416 as assessed by intravital multi-fluorescence videomicroscopy Neoplasia 1 1999 31 41
61. P. Vajkoczy, M.D. Menger, and R. Goldbrunner Targeting angiogenesis inhibits tumor infiltration and expression of the pro-invasive protein SPARC Int J Cancer 87 2000 261 268